

# Contents

|          |                                                                                                                 |           |
|----------|-----------------------------------------------------------------------------------------------------------------|-----------|
| <b>1</b> | <b>Introduction: Discovery and Development—New Facet of Industry, New Tools and Lead Optimization . . . . .</b> | <b>1</b>  |
| 1.1      | Scope and Content of this Review . . . . .                                                                      | 2         |
| 1.2      | Drug Discovery and Development . . . . .                                                                        | 6         |
| 1.3      | Defining SB: Key Components . . . . .                                                                           | 7         |
| 1.4      | A Brief History of Systems Biology (SB): In Terms of Key Advances . . . . .                                     | 8         |
| 1.5      | Perspective and Potential Impact of Systems Biology on Academic Funding and Pharma R&D and Cost Savings . . .   | 9         |
|          | References . . . . .                                                                                            | 10        |
| <b>2</b> | <b>Discovery: Use of Systems Biology for Identifying Targets . . . . .</b>                                      | <b>11</b> |
| 2.1      | Identifying Targets and Druggability Space . . . . .                                                            | 12        |
| 2.1.1    | Bioinformatics Inputs (BI Inputs) . . . . .                                                                     | 14        |
| 2.2      | Combinatorial Chemistry Tools . . . . .                                                                         | 15        |
| 2.2.1    | BI Inputs . . . . .                                                                                             | 15        |
| 2.2.2    | Diversity Tools . . . . .                                                                                       | 16        |
| 2.2.3    | Qualitative and Quantitative Screens and Filters . . . . .                                                      | 19        |
| 2.2.4    | Structure-Activity Methods (SAR/QSAR) . . . . .                                                                 | 20        |
| 2.3      | Summarizing . . . . .                                                                                           | 21        |
|          | References . . . . .                                                                                            | 22        |
| <b>3</b> | <b>Integrative Systems Biology I—Biochemistry: Phase I Lead Discovery and Molecular Interactions . . . . .</b>  | <b>25</b> |
| 3.1      | Molecular Screens: Receptor–Ligand (R–L) Interaction and Molecular Modeling . . . . .                           | 26        |
| 3.1.1    | Molecular Modeling . . . . .                                                                                    | 27        |
| 3.1.2    | Quantum Chemistry . . . . .                                                                                     | 27        |
| 3.1.3    | Molecular Mechanics . . . . .                                                                                   | 27        |
| 3.1.4    | Molecular Dynamics . . . . .                                                                                    | 28        |

|          |                                                                                                                                                    |           |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 3.1.5    | Receptor Based QSAR Methods . . . . .                                                                                                              | 28        |
| 3.1.6    | Biomimetics . . . . .                                                                                                                              | 28        |
| 3.2      | Collateral Efficacy and Permissive Antagonism . . . . .                                                                                            | 29        |
| 3.3      | Co-Drugging: Multiple Targets, Combination<br>Therapy & Multistage Targeting. . . . .                                                              | 29        |
| 3.3.1    | Multicomponent Drugs . . . . .                                                                                                                     | 30        |
| 3.3.2    | Multi-Target Approach . . . . .                                                                                                                    | 30        |
| 3.3.3    | Multi-Stage Targeting . . . . .                                                                                                                    | 31        |
| 3.4      | Text Mining for Interactions . . . . .                                                                                                             | 31        |
| 3.5      | Employment of Biochemical Networks . . . . .                                                                                                       | 32        |
| 3.6      | Overview of Deterministic Models . . . . .                                                                                                         | 32        |
| 3.6.1    | Emergence . . . . .                                                                                                                                | 33        |
| 3.6.2    | Reactome . . . . .                                                                                                                                 | 34        |
| 3.7      | Bioinformatics . . . . .                                                                                                                           | 34        |
| 3.8      | Summarizing . . . . .                                                                                                                              | 36        |
|          | References . . . . .                                                                                                                               | 36        |
| <b>4</b> | <b>Integrative Systems Biology II—Molecular Biology:</b>                                                                                           |           |
|          | <b>Phase 2 Lead Discovery and <i>In Silico</i> Screening . . . . .</b>                                                                             | <b>39</b> |
| 4.1      | OMICs . . . . .                                                                                                                                    | 40        |
| 4.1.1    | BI Inputs . . . . .                                                                                                                                | 40        |
| 4.1.2    | Metabolomics . . . . .                                                                                                                             | 41        |
| 4.2      | Chemogenomics . . . . .                                                                                                                            | 42        |
| 4.2.1    | BI Inputs . . . . .                                                                                                                                | 42        |
| 4.3      | Morphogenics . . . . .                                                                                                                             | 43        |
| 4.4      | Minimal Phenotype and Synthetic Biology . . . . .                                                                                                  | 43        |
| 4.4.1    | SB and BI Inputs . . . . .                                                                                                                         | 44        |
| 4.5      | Reconstructing Biological Networks . . . . .                                                                                                       | 44        |
| 4.6      | Summarizing . . . . .                                                                                                                              | 46        |
|          | References . . . . .                                                                                                                               | 47        |
| <b>5</b> | <b>Discovery: Computational Systems Biology (CSB) in Health<br/>and Disease I . . . . .</b>                                                        | <b>51</b> |
| 5.1      | Cellular Environment: Network Reconstruction<br>and Inference from Experimental Data . . . . .                                                     | 52        |
| 5.2      | Reconstructing Gene Networks. . . . .                                                                                                              | 54        |
| 5.3      | Data Mining and Heuristic Data Preprocessing Tools . . . . .                                                                                       | 54        |
| 5.4      | Analysis of Disease ‘Correlation Network <sup>TM</sup> ,<br>and Concerted Metabolic Activation: Disease as a Systems<br>Network Property . . . . . | 55        |
| 5.5      | Challenges for Stem Cells: Control. . . . .                                                                                                        | 58        |
| 5.5.1    | SB and BI Inputs . . . . .                                                                                                                         | 58        |
| 5.6      | Emergent Properties . . . . .                                                                                                                      | 59        |
| 5.7      | Computational Systems Biology . . . . .                                                                                                            | 60        |

|          |                                                                                                 |            |
|----------|-------------------------------------------------------------------------------------------------|------------|
| 5.8      | Summarizing . . . . .                                                                           | 63         |
|          | References . . . . .                                                                            | 64         |
| <b>6</b> | <b>Development: In Vivo Pharmacology—Systems Biology<br/>in Health and Disease II . . . . .</b> | <b>69</b>  |
| 6.1      | Animal Disease Models . . . . .                                                                 | 70         |
| 6.1.1    | Gene Knockout Animal Models . . . . .                                                           | 71         |
| 6.2      | Pheno- and Genotyping . . . . .                                                                 | 71         |
| 6.3      | RNA Interference . . . . .                                                                      | 72         |
| 6.3.1    | BI Inputs . . . . .                                                                             | 73         |
| 6.4      | Pharmacogenomics . . . . .                                                                      | 73         |
| 6.4.1    | SB and BI Inputs . . . . .                                                                      | 73         |
| 6.5      | In Silico Pharmacology: Future . . . . .                                                        | 74         |
| 6.6      | Summarizing . . . . .                                                                           | 75         |
|          | References . . . . .                                                                            | 76         |
| <b>7</b> | <b>Development: Pharmacokinetics—Systems Biology<br/>in Health and Disease III . . . . .</b>    | <b>77</b>  |
| 7.1      | Microdosing in PK . . . . .                                                                     | 78         |
| 7.1.1    | BI Inputs . . . . .                                                                             | 78         |
| 7.2      | Adaptive Trial Design . . . . .                                                                 | 78         |
| 7.3      | Equilibrium Versus Non-Equilibrium PK Models . . . . .                                          | 79         |
| 7.4      | Toxicity Biomarkers . . . . .                                                                   | 80         |
| 7.4.1    | SB and BI Inputs . . . . .                                                                      | 80         |
| 7.5      | In Silico Toxicity Prediction . . . . .                                                         | 81         |
| 7.6      | Quantitative PKPD/Tox Modeling . . . . .                                                        | 82         |
| 7.7      | Summarizing . . . . .                                                                           | 83         |
|          | References . . . . .                                                                            | 84         |
| <b>8</b> | <b>Development: Multiscale CSB—Simulation Tools . . . . .</b>                                   | <b>87</b>  |
| 8.1      | Defining CSB . . . . .                                                                          | 88         |
| 8.2      | Redefining (and Discovering) Emergent Properties<br>at Higher-Level Hierarchies . . . . .       | 91         |
| 8.3      | Virtual Organs, Disease Models, Virtual Patient . . . . .                                       | 92         |
| 8.4      | Population Level Model: Towards Individualized Medicine . . . . .                               | 93         |
| 8.5      | Targeting Networks: Towards Organismic,<br>Full-Scale Design . . . . .                          | 94         |
| 8.6      | Redefining the Traditional R&D Paradigm . . . . .                                               | 95         |
| 8.7      | Summarizing . . . . .                                                                           | 99         |
|          | References . . . . .                                                                            | 99         |
| <b>9</b> | <b>Development: Drug Formulation and Delivery . . . . .</b>                                     | <b>103</b> |
| 9.1      | Targeting Concept and Mechanisms . . . . .                                                      | 103        |
| 9.1.1    | SB and BI Inputs . . . . .                                                                      | 104        |

|           |                                                                                       |            |
|-----------|---------------------------------------------------------------------------------------|------------|
| 9.2       | Nanoscale Drug Delivery Systems . . . . .                                             | 105        |
| 9.3       | CSB at Formulation and Delivery. . . . .                                              | 105        |
| 9.4       | Summarizing . . . . .                                                                 | 106        |
|           | References . . . . .                                                                  | 106        |
| <b>10</b> | <b>Development: Preclinical Model Based Drug Development. . . . .</b>                 | <b>109</b> |
| 10.1      | Defining MBDD. . . . .                                                                | 109        |
| 10.2      | Summarizing . . . . .                                                                 | 112        |
|           | References . . . . .                                                                  | 112        |
| <b>11</b> | <b>Systems Biology: Impact on Pharma and Biotech . . . . .</b>                        | <b>115</b> |
| 11.1      | SB Impact . . . . .                                                                   | 115        |
| 11.2      | Key Technologies and Tools Needed for Development<br>of Systems Biology/CSB . . . . . | 120        |
| 11.3      | Steps in System Biology/CSB . . . . .                                                 | 120        |
| 11.4      | Benefits of Systems Biology and CSB . . . . .                                         | 123        |
| 11.5      | Summary . . . . .                                                                     | 123        |
|           | References . . . . .                                                                  | 127        |

Systems Biology in Biotech & Pharma

A Changing Paradigm

Prokop, A.; Michelson, S.

2012, XVIII, 127 p. 16 illus. in color., Softcover

ISBN: 978-94-007-2848-6